It is well known that survival of patients with advanced squamous-cell carcinoma of the head and neck (SCCHN) has not significantly improved despite recent advances in radiation and chemotherapy treatment. Specifically, a very low objective response rate can be obtained in patients with recurrent SC
Neoadjuvant cisplatin and interferonα-2b (IFNα-2b) with 13-cis retinoic acid (13-cRA) in bulky squamous cell carcinoma of the cervix stage IB and IIA
✍ Scribed by W. Termrunguanglert; D. Tresukosol; T. Sittisomwong; A. Vasuratna; R. Lerkhachonsuk; P. Worasethsin; S. Triratanachat; S. Niruthisard; N. Sirisabya
- Book ID
- 117125857
- Publisher
- Elsevier Science
- Year
- 2000
- Tongue
- English
- Weight
- 164 KB
- Volume
- 70
- Category
- Article
- ISSN
- 0020-7292
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## BACKGROUND. Interferon in combination with 5-fluorouracil has been shown to be active in squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus. 13-cis-retinoic acid (CRA) has chemopreventive activity in SCC of the head and neck, and, in combination with interferon, has antitumo
## Abstract ## Background. We have previously conducted phase II trials with a combination of 13‐__cis__‐retinoic acid (13‐cRA), interferon‐α2a (IFN‐α2a), and α‐tocopherol (α‐TF) in patients with advanced oral premalignant lesions and locally advanced head and neck cancer in the adjuvant settings